Aralez Pharmaceuticals Canada Inc.
Records under this name other than the patents Aralez Pharmaceuticals Canada Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
Showing 1 to 7 of 7 · Back to Aralez Pharmaceuticals Canada Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,861,579 | Foamable Formulation Lapsed on the fee record Ended Jan 9, 2026 · High confidence | Lapsed on the fee record | Ended Jan 9, 2026 | High confidence |
| US 7,772,210 | Cystitis Treatment with High Dose Chondroitin Sulfate Term ended Term ended Nov 7, 2024 · High confidence | Term ended | Term ended Nov 7, 2024 | High confidence |
| US 10,646,441 | Foamable Formulation Lapsed on the fee record Ended May 12, 2024 · High confidence | Lapsed on the fee record | Ended May 12, 2024 | High confidence |
| US 8,084,441 | Cystitis Treatment with High Dose Chondroitin Sulfate Term ended Ended no later than Feb 19, 2023 · Low confidence | Term ended | Ended no later than Feb 19, 2023 | Low confidence |
| US 8,334,276 | Cystitis Treatment with High Dose Chondroitin Sulfate Term ended Term ended Feb 19, 2023 · High confidence | Term ended | Term ended Feb 19, 2023 | High confidence |
| US 8,778,908 | Cystitis Treatment with High Dose Chondroitin Sulfate Term ended Term ended Feb 19, 2023 · High confidence | Term ended | Term ended Feb 19, 2023 | High confidence |
| US 6,083,933 | Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution Term ended Term ended Apr 19, 2019 · From the USPTO record | Term ended | Term ended Apr 19, 2019 | From the USPTO record |